Metreleptin improves blood glucose in patients with insulin receptor mutations

JCEM: 8/22/13

Context: Rabson-Mendenhall syndrome (RMS) is caused by mutations of the insulin receptor, and results in extreme insulin resistance and dysglycemia. Hyperglycemia in RMS is very difficult to treat, and patients are at risk for early morbidity and mortality from complications of diabetes.

Objective: To study one year effects of recombinant human methionyl leptin (metreleptin) in five patients with RMS, and ten year effects in two of these patients. Read more